Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

2,869 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY GUIDELINES FOR MANAGEMENT OF DYSLIPIDEMIA AND PREVENTION OF CARDIOVASCULAR DISEASE.
Jellinger PS, Handelsman Y, Rosenblit PD, Bloomgarden ZT, Fonseca VA, Garber AJ, Grunberger G, Guerin CK, Bell DSH, Mechanick JI, Pessah-Pollack R, Wyne K, Smith D, Brinton EA, Fazio S, Davidson M. Jellinger PS, et al. Among authors: davidson m. Endocr Pract. 2017 Apr;23(Suppl 2):1-87. doi: 10.4158/EP171764.APPGL. Endocr Pract. 2017. PMID: 28437620
AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY GUIDELINES FOR MANAGEMENT OF DYSLIPIDEMIA AND PREVENTION OF CARDIOVASCULAR DISEASE - EXECUTIVE SUMMARYComplete Appendix to Guidelines available at http://journals.aace.com.
Jellinger PS, Handelsman Y, Rosenblit PD, Bloomgarden ZT, Fonseca VA, Garber AJ, Grunberger G, Guerin CK, Bell DSH, Mechanick JI, Pessah-Pollack R, Wyne K, Smith D, Brinton EA, Fazio S, Davidson M, Zangeneh F, Bush MA. Jellinger PS, et al. Among authors: davidson m. Endocr Pract. 2017 Apr 2;23(4):479-497. doi: 10.4158/EP171764.GL. Epub 2017 Feb 3. Endocr Pract. 2017. PMID: 28156151
Effects of anacetrapib on plasma lipids in specific patient subgroups in the DEFINE (Determining the Efficacy and Tolerability of CETP INhibition with AnacEtrapib) trial.
Brinton EA, Kher U, Shah S, Cannon CP, Davidson M, Gotto AM, Ashraf TB, McCrary Sisk C, Dansky H, Mitchel Y, Barter P; DEFINE Investigators. Brinton EA, et al. Among authors: davidson m. J Clin Lipidol. 2015 Jan-Feb;9(1):65-71. doi: 10.1016/j.jacl.2014.10.005. Epub 2014 Nov 4. J Clin Lipidol. 2015. PMID: 25670362 Clinical Trial.
Measurement of LDL-C after treatment with the CETP inhibitor anacetrapib.
Davidson M, Liu SX, Barter P, Brinton EA, Cannon CP, Gotto AM Jr, Leary ET, Shah S, Stepanavage M, Mitchel Y, Dansky HM. Davidson M, et al. J Lipid Res. 2013 Feb;54(2):467-72. doi: 10.1194/jlr.M032615. Epub 2012 Nov 19. J Lipid Res. 2013. PMID: 23172660 Free PMC article.
Design of the DEFINE trial: determining the EFficacy and tolerability of CETP INhibition with AnacEtrapib.
Cannon CP, Dansky HM, Davidson M, Gotto AM Jr, Brinton EA, Gould AL, Stepanavage M, Liu SX, Shah S, Rubino J, Gibbons P, Hermanowski-Vosatka A, Binkowitz B, Mitchel Y, Barter P; DEFINE investigators. Cannon CP, et al. Among authors: davidson m. Am Heart J. 2009 Oct;158(4):513-519.e3. doi: 10.1016/j.ahj.2009.07.028. Am Heart J. 2009. PMID: 19781408 Clinical Trial.
Evaluation of lipids, drug concentration, and safety parameters following cessation of treatment with the cholesteryl ester transfer protein inhibitor anacetrapib in patients with or at high risk for coronary heart disease.
Gotto AM Jr, Cannon CP, Li XS, Vaidya S, Kher U, Brinton EA, Davidson M, Moon JE, Shah S, Dansky HM, Mitchel Y, Barter P; DEFINE Investigators. Gotto AM Jr, et al. Among authors: davidson m. Am J Cardiol. 2014 Jan 1;113(1):76-83. doi: 10.1016/j.amjcard.2013.08.041. Epub 2013 Oct 4. Am J Cardiol. 2014. PMID: 24188894 Clinical Trial.
Safety of anacetrapib in patients with or at high risk for coronary heart disease.
Cannon CP, Shah S, Dansky HM, Davidson M, Brinton EA, Gotto AM, Stepanavage M, Liu SX, Gibbons P, Ashraf TB, Zafarino J, Mitchel Y, Barter P; Determining the Efficacy and Tolerability Investigators. Cannon CP, et al. Among authors: davidson m. N Engl J Med. 2010 Dec 16;363(25):2406-15. doi: 10.1056/NEJMoa1009744. Epub 2010 Nov 17. N Engl J Med. 2010. PMID: 21082868 Free article. Clinical Trial.
Mipomersen, an apolipoprotein B synthesis inhibitor, reduces atherogenic lipoproteins in patients with severe hypercholesterolemia at high cardiovascular risk: a randomized, double-blind, placebo-controlled trial.
Thomas GS, Cromwell WC, Ali S, Chin W, Flaim JD, Davidson M. Thomas GS, et al. Among authors: davidson m. J Am Coll Cardiol. 2013 Dec 10;62(23):2178-84. doi: 10.1016/j.jacc.2013.07.081. Epub 2013 Sep 4. J Am Coll Cardiol. 2013. PMID: 24013058 Free article. Clinical Trial.
2,869 results